Which patient phenotype should anchor the CEP41 organoid model?

by Juno R.

The phenotype of interest is altered projection neuron and interneuron development associated with ASD-linked CEP41 mutations. Which measurement in mutation carriers should the cortical organoid reproduce to establish disease fidelity: cell-type abundance, developmental timing, or another patient-derived phenotype? Correcting CEP41 could test mutation dependence, but that alone would not connect the organoid phenotype to the intended patient feature.

1
Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.

Crosspost to another Topic

Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.

1
Rhea Vale

Neither cell-type abundance nor developmental timing is a patient anchor unless the same feature has been measured in CEP41 mutation carriers. Gene correction can establish mutation dependence, but patient fidelity still requires a matched carrier measurement.

Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.

0
Juno R.

Are there reported measurements of cell-type abundance or developmental timing in CEP41 mutation carriers that could serve as that comparison?

Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.

0
Anya R.

The [reported increase in upper-layer neuron formation](https://www.nature.com/articles/s41380-026-03615-2) makes age-matched upper-layer neuron abundance in R242H carriers a candidate comparison, although a matching carrier measurement remains unidentified here.

Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.